Crosstalk Between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression
Overview
Authors
Affiliations
Purpose: To assess the clinical and pathologic significance of mast cell infiltration in human pancreatic cancer and evaluate crosstalk between mast cells and cancer cells in vitro.
Experimental Design: Immunohistochemistry for tryptase was done on 53 pancreatic cancer specimens. Mast cell counts were correlated with clinical variables and survival. Serum tryptase activity from patients with cancer was compared with patients with benign pancreatic disease. In vitro, the effect of pancreatic cancer-conditioned medium on mast cell migration was assessed. The effect of conditioned medium from the human mast cell line, LAD-2, on cancer and normal ductal cell proliferation was assessed by thymidine incorporation. Matrigel invasion assays were used to evaluate the effect of mast cell-conditioned medium on cancer cell invasion in the presence and absence of a matrix metalloproteinase inhibitor, GM6001.
Results: Mast cell infiltration was significantly increased in pancreatic cancer compared with normal pancreatic tissue (11.4 +/- 6.7 versus 2.0 +/- 1.4, P < 0.001). Increased infiltrating mast cells correlated with higher grade tumors (P < 0.0001) and worse survival. Patients with pancreatic cancer had elevated serum tryptase activity (P < 0.05). In vitro, AsPC1 and PANC-1 cells induced mast cell migration. Mast cell-conditioned medium induced pancreatic cancer cell migration, proliferation, and invasion but had no effect on normal ductal cells. Furthermore, the effect of mast cells on cancer cell invasion was, in large part, matrix metalloproteinase-dependent.
Conclusions: Tumor-infiltrating mast cells are associated with worse prognosis in pancreatic cancer. In vitro, the interaction between mast cells and pancreatic cancer cells promotes tumor growth and invasion.
Mast Cell Density in Squamous Cell Carcinoma of Skin in Dogs and Cats.
Juodziukyniene N, Lasiene K, Savickiene N, Aniuliene A Animals (Basel). 2025; 15(3).
PMID: 39943085 PMC: 11816034. DOI: 10.3390/ani15030316.
Zhou Y, Zhang Y, Zhou Y, Gu Y, Chen Y, Wang J Discov Oncol. 2025; 16(1):18.
PMID: 39775403 PMC: 11711411. DOI: 10.1007/s12672-025-01752-8.
Sitte A, Goess R, Tufekci T, Pergolini I, Pfitzinger P, Salvo-Romero E Sci Rep. 2024; 14(1):26285.
PMID: 39487177 PMC: 11530627. DOI: 10.1038/s41598-024-77010-8.
Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer.
Ma Y, Zhao X, Feng J, Qiu S, Ji B, Huang L iScience. 2024; 27(11):111085.
PMID: 39473974 PMC: 11514315. DOI: 10.1016/j.isci.2024.111085.
Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?.
Ouissam A, Hind C, Sami Aziz B, Said A Ther Adv Med Oncol. 2024; 16:17588359241284911.
PMID: 39399412 PMC: 11468005. DOI: 10.1177/17588359241284911.